公开(公告)号：US12252493B2

公开(公告)日：2025-03-18

申请号：US17615778

申请日：2020-06-03

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  John Michael Ketcham ,  Aaron Craig Burns

IPC: C07D487/04

Abstract: Disclosed are compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, disclosed are compounds of Formula (I) and pharmaceutical compositions thereof, and methods of using the compounds and pharmaceutical compositions in, for example, methods of treating cancer.

公开(公告)号：US20250059182A1

公开(公告)日：2025-02-20

申请号：US18571051

申请日：2022-06-21

Applicant: Mirati Therapeutics, Inc.

Inventor： John Michael Ketcham ,  Christopher Ronald Smith ,  Matthew Arnold Marx ,  Xiaolun Wang ,  Aaron Craig Burns ,  Svitlana Kulyk ,  Anthony Ivetac ,  John David Lawson

IPC: C07D471/04 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/5377 ,  A61K31/5386 ,  C07D237/34 ,  C07D403/04 ,  C07D405/12 ,  C07D413/04 ,  C07D487/04 ,  C07D519/00

Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

公开(公告)号：US20240398815A1

公开(公告)日：2024-12-05

申请号：US18794390

申请日：2024-08-05

Applicant: MIRATI THERAPEUTICS, INC.

Inventor： Cletus NUNES ,  Mehrdad KHEIRIPOUR ,  Monika GAVIREDDI

IPC: A61K31/519 ,  A61K9/00 ,  A61K9/20 ,  A61K9/28

Abstract: Pharmaceutical compositions in solid form comprising adagrasib, suitable for oral dosage to treat subjects having cancer; as well as methods of manufacturing the compositions, and methods of treating cancer.

公开(公告)号：US20240368153A1

公开(公告)日：2024-11-07

申请号：US18572110

申请日：2022-06-29

Applicant: Mirati Therapeutics, Inc.

Inventor： Christopher Ronald Smith ,  Svitlana Kulyk ,  Matthew Arnold Marx ,  John David Lawson ,  Anthony Ivetac ,  Xiaolun Wang ,  Aaron Craig Burns

IPC: C07D471/04 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/498 ,  A61K31/506 ,  A61K31/551 ,  C07D471/14 ,  C07D495/04

Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

公开(公告)号：US20240309020A1

公开(公告)日：2024-09-19

申请号：US18644056

申请日：2024-04-23

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Xiaolun Wang ,  Aaron Craig Burns ,  James Gail Christensen ,  John Michael Ketcham ,  John David Lawson ,  Matthew Arnold Marx ,  Christopher Ronald Smith ,  Shelley Allen ,  James F. Blake ,  Mark Joseph Chicarelli ,  Joshua Ryan Dahlke ,  Donghua Dai ,  Jay Bradford Fell ,  John Peter Fischer ,  Macedonio J. Mejia ,  Brad Newhouse ,  Phong Nguyen ,  Jacob Matthew O'Leary ,  Spencer Pajk ,  Martha E. Rodriguez ,  Pavel Savechenkov ,  Tony P. Tang ,  Guy P.A. Vigers ,  Qian Zhao ,  Dean Russell Kahn ,  John Gaudino ,  Michael Christopher Hilton

IPC: C07D519/00

CPC classification number: C07D519/00

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20240228510A1

公开(公告)日：2024-07-11

申请号：US18286961

申请日：2022-04-14

Applicant: Mirati Therapeutics, Inc.

Inventor： Aaron Craig Burns ,  James Gail Christensen ,  John David Lawson ,  Matthew Arnold Marx ,  Christopher Ronald Smith

IPC: C07D519/00 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/496 ,  C07D471/04

CPC classification number: C07D519/00 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/496 ,  C07D471/04

Abstract: The present invention relates to compounds that inhibit KRas G12C; in particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20240208912A1

公开(公告)日：2024-06-27

申请号：US18549864

申请日：2022-03-11

Applicant: Mirati Therapeutics, Inc.

Inventor： Thomas P. Bobinski ,  Christopher Ronald Smith ,  Matthew Arnold Marx ,  John Michael Ketcham ,  Aaron Craig Burns ,  John David Lawson ,  Svitlana Kulyk ,  Jon Kuehler ,  Anthony Ivetac

IPC: C07D237/34 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04

CPC classification number: C07D237/34 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04

Abstract: Disclosed are compounds of Formula IIA, IA-1, IIB, IIB-1, IIC and IIC-1: and pharmaceutical compositions and methods of use thereof These compounds inhibit Protein Arginine M-Methyl Transferase 5 (PRMT5) activity and are useful in methods and pharmaceutical compositions for treating cancer.

公开(公告)号：US11964989B2

公开(公告)日：2024-04-23

申请号：US17869575

申请日：2022-07-20

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Xiaolun Wang ,  Aaron Craig Burns ,  James Gail Christensen ,  John Michael Ketcham ,  John David Lawson ,  Matthew Arnold Marx ,  Christopher Ronald Smith ,  Shelley Allen ,  James F. Blake ,  Mark Joseph Chicarelli ,  Joshua Ryan Dahlke ,  Donghua Dai ,  Jay Bradford Fell ,  John Peter Fischer ,  Macedonio J. Mejia ,  Brad Newhouse ,  Phong Nguyen ,  Jacob Matthew O'Leary ,  Spencer Pajk ,  Martha E. Rodriguez ,  Pavel Savechenkov ,  Tony P. Tang ,  Guy P.A. Vigers ,  Qian Zhao ,  Dean Russell Kahn ,  John Gaudino ,  Michael Christopher Hilton

IPC: C07D519/00

CPC classification number: C07D519/00

Abstract: Compounds that inhibit KRas G12D. In particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I):




or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230373999A1

公开(公告)日：2023-11-23

申请号：US18048834

申请日：2022-10-21

Applicant: MIRATI THERAPEUTICS, INC. ,  ARRAY BIOPHARMA INC.

Inventor： Matthew Arnold MARX ,  James Gail CHRISTENSEN ,  Christopher Ronald SMITH ,  James F. BLAKE ,  Laurence E. BURGESS ,  Mark Joseph CHICARELLI ,  Adam COOK ,  Jay Bradford FELL ,  John P. FISCHER ,  Macedonio J. MEJIA ,  Martha E. RODRIGUEZ ,  Pavel SAVECHENKOV ,  Tony P. TANG ,  Guy P.A. VIGERS

IPC: C07D471/04 ,  A61P35/00 ,  C07D491/08

CPC classification number: C07D471/04 ,  A61P35/00 ,  C07D491/08

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US11787819B2

公开(公告)日：2023-10-17

申请号：US17691658

申请日：2022-03-10

Applicant: Mirati Therapeutics, Inc.

Inventor： Patricia Andres ,  Ekaterina Albert ,  Emily Rigsbee ,  Zhiwei Cao ,  Dalian Zhao ,  Zhonghua Zhang

IPC: C07D495/04 ,  A61P35/00

CPC classification number: C07D495/04 ,  C07B2200/13

Abstract: The present invention relates to malate salt of a multi-tyrosine kinase inhibitor. In particular, the present invention relates to crystalline forms of the malate salt of multi-tyrosine kinase inhibitor N-(3-fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-hydroxysuccinate (1:1), pharmaceutical compositions comprising the crystalline form, processes for preparing the crystalline form and methods of use therefore.